查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1808345

低温运输医药市场按产品类型、包装类型、温度范围、设备、服务类型、应用和最终用户划分－2025-2030 年全球预测

Cold-chain Pharma Market by Product Type, Packaging Type, Temperature Range, Equipment, Service Type, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2024年低温运输医药市场规模将达153.9亿美元，到2025年将以9.11%的复合年增长率成长至167.8亿美元，到2030年将达到259.8亿美元。

主要市场统计数据
基准年2024年 153.9亿美元
预计2025年 167.8亿美元
预测年份 2030 259.8亿美元
复合年增长率（%） 9.11%

简要介绍快速发展的全球医疗保健生态系统中医药低温运输物流的复杂性和战略重要性

低温运输医药生态系统是一个复杂的交叉领域，融合了科学、物流和法律规范，是现代药物传递的基础。生技药品、细胞和基因疗法以及新一代疫苗的进步，提高了产品在时间和距离上保持完整性所需的技术严谨性，同时也扩大了必须合作以维持合规温度曲线的利益相关人员的数量。

随着技术、监管环境和以患者为中心的分销模式对营运产生影响，变革性变化正在改变低温运输医药格局

随着技术、法规和客户期望的融合，产业动态正在迅速变化，重新定义有效的低温运输营运。数位化和遥测技术已从试点阶段发展成为必不可少的控制措施，持续温度监控、预测分析和基于区块链的可追溯性也日益渗透到整个仓储和运输环节，从而加快了异常处理速度，并提高了监管透明度。

评估近期美国关税和 2025 年贸易政策变化如何影响供应链成本压力和路线决策的改变

美国近期推出的关税和贸易政策变化（预计到2025年）为低温运输医药网络带来了新的成本和路线考量。关税正在改变采购和跨境运输的经济性，影响企业的生产、仓储和最终加工地点。事实上，企业已采取应对措施，包括多元化供应商基础、重新调整入境路线决策，并更依赖区域化网络，以降低关税波动带来的风险，并维持对时间敏感的冷链运输。

详细细分，确定产品类型、包装、温度控制、设备、服务、应用和最终用户如何推动营运设计

精细的细分视角可以明确操作的复杂性所在，以及哪些功能能够最大程度地降低风险。不同产品类型之间存在显着差异。生技药品需要针对单株抗体、血浆衍生疗法和重组蛋白的通讯协定，这与血液和血浆製品（例如凝血因子和免疫球蛋白）的处理和储存需求不同。细胞和基因疗法具有独特的限制，同种异体和自体细胞和基因疗法通常需要用于临床试验材料（包括套件和临床实验药物）的低温炼和专用辅助器具。胰岛素和肽激素的设计需要考虑GLP-1和胰岛素变异体，而特殊药物（包括生育药物和专用注射）则需要客製化的处理和交付时间表。疫苗种类繁多，从大流行疫苗和新兴疫苗到常规免疫接种、旅行疫苗和特殊疫苗。大流行疫苗引入了mRNA和病毒载体的子类别，这些子类别对低温储存提出了独特的要求。

美洲、欧洲、中东和非洲以及亚太地区的动态和基础设施差异是低温运输策略的差异化因素

美洲、欧洲、中东和非洲以及亚太地区的区域基础设施、管理体制和商业惯例差异巨大，导致营运环境差异巨大，需要製定量身定制的策略。在美洲，成熟的温控仓库、强大的航空货运网络以及不断发展的最后一英里生态系统支持快速商业化，但地域辽阔和地区监管差异通常意味着，区域枢纽和合格的最后一英里合作伙伴是实现全国覆盖的先决条件。

塑造低温运输医药生态系统的竞争与协作企业行为，包括合作伙伴关係、专业化和差异化服务

我们看到，低温运输医药领域的企业正将专业化、伙伴关係和垂直整合结合，以追求竞争优势。一些供应商专注于深度技术领域，例如超低温物流、超低温储存或以临床试验为中心的服务，投资于独特的处理通讯协定、专业的设备团队和严格的资格认证程序，以在产品安全性和可靠性方面脱颖而出。其他参与者则强调服务广度，提供集存储、运输、合规服务和数位视觉性于一体的端到端解决方案，从而简化製造商和医疗保健提供者的供应商管理。

为高阶主管提供切实可行的建议，透​​过投资、伙伴关係、合规和人才策略确保低温运输业务的未来发展

主管必须采取多管齐下的策略，确保低温运输营运面向未来，并在日益严苛的环境中获取价值。首先，优先投资于可视性和分析技术，提供跨运输和仓储的即时遥测数据，从而实现主动异常管理和增强的审核追踪。此外，还要透过流程控制、严格的资格确认通讯协定和定期审核来补充技术投资，确保数据得到经过检验的程序支援。

透明的调查方法，详细说明低温运输评估的资料来源、检验程序、相关人员访谈和分析框架

调查方法结合了主要和次要证据流，建构了严谨透明的分析基础。主要输入包括对製造商、物流供应商和临床试验机构的供应链、品质和监管负责人进行结构化访谈，并辅以现场操作考察和流程演练，检验设施、包装和温控实践。这些访谈重点关注通道检验经验、最后一哩例外情况和设备资格确认了解实际的限制因素和缓解措施。

总结弹性合规的低温运输医药运输的战略意义、持续风险和现实前进道路

最后，低温运输医药产业正处于曲折点，产品创新、监管严谨性和地缘政治动态共同作用，提升了卓越营运的标准。积极协调遥测、高效包装和区域网路灵活性投资的组织可以降低风险，并加快关键治疗方法的可及性。同时，不断变化的贸易政策和日益复杂的产品系列需要动态采购、完善的资格确认实践和更强有力的合约保护，以保持连续性。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章市场动态

  • 整合区块链追踪平台，实现端到端低温运输可视性和合规性
  • 引入支援物联网的智慧包装解决方案，即时监控关键温度偏差
  • 扩大超低温储存基础设施，支持 mRNA 疫苗的全球分发
  • 将环保、可生物降解的隔热材料引入低温运输运输包装
  • 生物製药公司与专业第三方物流公司建立策略伙伴关係，实现最后一哩温控配送
  • 监管协调努力旨在简化跨境物流并减少合规延误
  • 在自体细胞和基因治疗中，从血液分离到输注，透过冷冻保存快速识别和储存个体
  • 实施人工智慧车道风险评分和预测性 ETD/ETA 规划，主动避开容易延误和偏差的路线
  • 机场和航空公司对 CEIV Pharma 设施和冷藏干燥机的投资确保了药品运输的完整性
  • 使用数位双胞胎和稳定性模型来设计强大的低温运输流程并主动管理累积热暴露

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章 2025年美国关税的累积影响

第八章低温运输药品市场（依产品类型）

  • 生物製药
    • 单株抗体
    • 血浆衍生疗法
    • 重组蛋白和酶
  • 血液/血浆製品
    • 凝血因子
    • 免疫球蛋白
  • 细胞和基因治疗
    • 同种异体细胞治疗
    • 自体细胞治疗
    • 基因治疗
  • 临床试验材料
    • 配件和套件
    • 临床实验药物
  • 胰岛素和荷尔蒙
    • GLP-1和其他肽激素
    • 胰岛素
  • 特种製药
    • 不孕不育治疗及生殖医学
    • 特殊注射
  • 疫苗
    • 流行病和新兴疫苗
      • mRNA疫苗
      • 病毒载体疫苗
    • 常规疫苗接种
    • 旅行和特殊疫苗

第九章低温运输药品市场（依包装类型）

  • 活性包装
  • 被动封装

第 10 章低温运输药品市场（依温度范围）

  • 极低温（-150℃以下）
    • 低温包装
    • 干散货运输
    • LN2蒸气储存
  • 冷冻（-20至-40°C）
    • 包裹
    • 贮存
    • 运输
  • 冷藏（2-8°C）
    • 包裹
    • 贮存
    • 运输
  • 超低温（-60至-86°C）
    • 包裹
    • 贮存
    • 运输

第11章低温运输药品市场（按设备）

  • 仓储设备
    • 冷藏室和仓库
    • 低温冷冻库和液态氮冷却罐
    • 冷冻库（-20℃级）
    • 药品冷藏箱（2-8℃）
    • 超低温冰箱（-80℃）
  • 运输设备
    • 空运货柜（ULD）
    • 最后一英里可携式冷却器
    • 冷藏海运货柜
    • 冷藏卡车和货车

第十二章低温运输医药市场（依服务类型）

  • 临床试验物流
    • 辅助管理
    • 直接患者服务
    • 现场供应和退货
  • 合规性和品质
    • 审核和GDP培训
    • 车道检验和风险评估
    • 资质（IQ/OQ/PQ）
  • 储存/仓储
    • 低温储存
    • 长期 GMP 储存
  • 运输
    • 首英里接送
    • 最后一哩配送
    • 远距
    • 逆向物流和退货

第十三章低温运输药品市场（按应用）

  • 临床试验
  • 商业分销
  • 直接送达患者/送货上门
  • 人道援助和非政府组织供应
  • 专业药房履约
  • 疫苗宣传活动

第十四章低温运输药品市场（依最终用户）

  • 血库和血浆中心
  • 临床试验设施和仓库
  • CMO 和 CDMO
  • CRO
  • 医院和诊所
  • 製药和生物技术製造商
    • 新兴生物技术
    • 大型製药公司
  • 零售和专业药局
  • 疫苗接种中心和公共卫生机构

15.美洲低温运输医药市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

16. 欧洲、中东和非洲低温运输药品市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

17. 亚太低温运输药品市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十八章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • DHL International GmbH
    • FedEx Corporation
    • Americold Realty Trust, Inc.
    • AmerisourceBergen Corporation
    • CH Robinson Worldwide, Inc.
    • Catalent, Inc.
    • Clinigen Group PLC
    • Conestoga Cold Storage Ltd.
    • Continental AG
    • CWT Ltd.
    • DB Schenker
    • DSV A/S
    • Emergent Cold LatAm Management LLC
    • HCL Technologies Limited
    • Helapet ltd.
    • Interstate Cold Storage, Inc.
    • JWD InfoLogistics Public Co. Ltd.
    • Keppel Telecommunications & Transportation Ltd,
    • Kerry Logistics Network Limited by SF Holding Co., Ltd.
    • Kuehne+Nagel Management AG
    • Lineage, Inc.
    • Maersk A/S
    • NewCold Cooperatief UA
    • OOCL Logistics Limited by COSCO SHIPPING Holdings Co. Limited
    • SCG Logistics Management Co Ltd.
    • Tiong Nam Logistics Holdings Berhad
    • United Parcel Service, Inc.
    • Ych Group
    • Yusen Logistics Group
    • BioCold Technologies SAS
    • FreezPak Logistics

第十九章 研究人工智慧

第20章 研究统计

第21章 研究联络人

第22章 研究报导

第23章 附录

Product Code: MRR-7E6E70985BD9

The Cold-chain Pharma Market was valued at USD 15.39 billion in 2024 and is projected to grow to USD 16.78 billion in 2025, with a CAGR of 9.11%, reaching USD 25.98 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 15.39 billion
Estimated Year [2025] USD 16.78 billion
Forecast Year [2030] USD 25.98 billion
CAGR (%) 9.11%

A concise introduction to the complexity and strategic importance of cold-chain logistics for pharmaceuticals in a rapidly evolving global healthcare ecosystem

The cold-chain pharmaceutical ecosystem is a complex intersection of science, logistics and regulatory oversight that underpins modern therapeutics delivery. Advances in biologics, cell and gene therapies, and next-generation vaccines have increased the technical stringency required to preserve product integrity across time and distance, while expanding the number of stakeholders who must coordinate to maintain compliant temperature profiles.

Against this backdrop, supply chain leaders face pressures from rising demand for direct-to-patient fulfillment, heightened regulatory scrutiny, and the need to balance speed with reliability. Operational decisions now extend from packaging selection to route design and last-mile execution, each with implications for clinical outcomes and commercial viability. Moreover, the industry must integrate new equipment classes, from ultra-low freezers to cryogenic storage and purpose-built transport assets, while ensuring qualification and validation across complex multimodal flows.

This introduction frames the subsequent analysis by highlighting the interplay between product complexity, temperature control regimes, and service modalities. It sets the stage for an evidence-driven examination of transformative forces influencing capital allocation, partnership strategies, and risk management across pharmaceutical cold chains.

Transformative shifts reshaping the cold-chain pharma landscape driven by technology, regulatory change, and patient-centric distribution models impacting operations

Industry dynamics are shifting at pace as technology, regulations and customer expectations converge to redefine what constitutes an effective cold-chain operation. Digitization and telemetry have moved from experimental pilots to essential controls; continuous temperature monitoring, predictive analytics and blockchain-based traceability are increasingly embedded across storage and transport, enabling faster exception handling and improved regulatory transparency.

Concurrently, regulatory frameworks are evolving to reflect product innovation and higher patient-safety requisites. Good Distribution Practice enforcement and lane validation expectations have expanded, prompting firms to strengthen qualification protocols and invest in independent audits and training. At the same time, the rise of patient-centric distribution models such as direct-to-patient services is forcing a rethink of packaging design, last-mile solutions and temperature resiliency to preserve both efficacy and patient experience.

Operationally, climate resilience and sustainability are reshaping procurement and equipment lifecycles; companies are evaluating energy-efficient ULT freezers, low-emission transport options and circular packaging strategies. Taken together, these transformative shifts demand integrated strategies that align technical capabilities, regulatory compliance and commercial imperatives to maintain product integrity and ensure timely access to critical medicines.

Assessing how recent US tariff measures and trade policy shifts through 2025 are aggregating supply chain cost pressure and altering routing decisions

Recent tariff actions and trade policy changes originating from the United States through 2025 have introduced new cost and routing considerations for cold-chain pharmaceutical networks. Tariff measures alter the economics of sourcing and cross-border movement, influencing where firms choose to locate manufacturing, storage and finishing activities. In practice, organizations have responded by diversifying supplier bases, recalibrating inbound lane decisions and increasing reliance on regionalized networks to reduce exposure to tariff volatility and preserve time-sensitive cold flows.

These trade shifts also interact with modal selection and inventory strategies. Where tariffs elevate landed costs, companies may favor higher-capacity, less frequent shipments to dilute fixed expenses, or alternatively move to nearshoring and regional manufacturing to minimize cross-border touchpoints. Such changes have downstream implications for packaging and equipment choices, particularly when different temperature ranges require specialized containers or cryogenic handling that complicates rerouting.

Moreover, tariff-related uncertainty places a premium on contractual agility and trade compliance capabilities. Organizations that invest in robust tariff classification, free trade agreement utilization and dynamic contract terms are better positioned to mitigate sudden policy moves. In addition, scenario planning and lane-level risk assessments have become standard tools for supply chain leaders seeking to preserve product integrity while optimizing cost and service under shifting trade conditions.

Deep segmentation clarity revealing how product types, packaging, temperature control, equipment, services, applications, and end users dictate operational design

A granular segmentation lens clarifies where operational complexity is concentrated and which capabilities deliver the greatest risk mitigation. Product-type distinctions matter: biologics demand protocols for monoclonal antibodies, plasma-derived therapeutics and recombinant proteins that differ from the handling and storage needs of blood and plasma products such as coagulation factors and immunoglobulins. Cell and gene therapies present their own constraints, with allogeneic and autologous cell therapies and gene therapies often requiring cryogenic chains or specialized ancillaries used in clinical trial materials, including kits and investigational medicinal products. Insulins and peptide hormones bring design considerations for GLP-1 and insulin variants, while specialty pharmaceuticals including fertility medicines and specialty injectables impose bespoke handling and delivery timelines. Vaccines span pandemic and emerging vaccines, routine immunization and travel or specialty vaccines, with pandemic vaccines introducing mRNA and viral vector subcategories that drive unique cold requirements.

Packaging choices influence reliability and flexibility across those product groups. Active packaging solutions provide powered temperature control for highly sensitive payloads, whereas passive packaging affords simpler, proven containment for many refrigerated and frozen flows. Temperature-range segmentation demands distinct options from cryogenic solutions at or below -150 °C with cryo packaging and dry shippers, to frozen and ultra-low classes and the ubiquitous refrigerated 2-8 °C band where packaging, storage and transportation modalities must be matched to product stability profiles.

Equipment selection reinforces these distinctions. Storage equipment spans from cold rooms and GMP warehouses to cryogenic freezers, LN2 tanks, pharmaceutical refrigerators and ultra-low freezers, while transport fleets encompass air cargo containers, last-mile portable coolers, ocean reefer containers and reefer trucks. Service types overlay these hardware choices: clinical trial logistics that include ancillary management and direct-to-patient services; compliance and quality offerings such as audits, GDP training and lane validation; storage and warehousing solutions that include cryogenic and long-term GMP storage; and transportation services covering first-mile, line-haul and last-mile delivery plus reverse logistics and returns. Application contexts shape operational priorities, whether supporting clinical trials, commercial distribution, home delivery, humanitarian supply, specialty pharmacy fulfilment or vaccination campaigns.

End-user needs ultimately drive configuration. Blood banks, clinical trial sites and depots, CMOs, CDMOs and CROs require different SLA and qualification intensity compared with hospitals, clinics, retail specialty pharmacies and public health vaccination centers. Pharma and biotech manufacturers, from emerging biotech to large pharmaceutical companies, often act as the integrators of these requirements, defining service levels, validation expectations and capital investment criteria. Understanding how each segment interacts with packaging, temperature regimes, equipment and service models is essential to designing resilient cold-chain solutions that are fit for purpose and scalable across therapeutic categories.

Regional dynamics and infrastructure contrasts across the Americas, Europe Middle East & Africa, and Asia-Pacific that drive differentiated cold-chain strategies

Regional infrastructure, regulatory regimes and commercial practices create materially different operating environments across the Americas, Europe Middle East & Africa, and Asia-Pacific, requiring tailored strategies for each geography. In the Americas, maturity in temperature-controlled warehousing, a strong air cargo network and a growing last-mile ecosystem support rapid commercialization, but vast distances and localized regulatory nuances mean that regional hubs and qualified last-mile partners are often prerequisites for nationwide coverage.

In Europe, Middle East & Africa, dense cross-border trade within the European Union coexists with highly variable capabilities across other markets, necessitating robust lane validation and comprehensive compliance programs to harmonize operations. The regulatory emphasis on GDP and lane qualification in many EMEA jurisdictions places a premium on audit-ready documentation and validated cold-chain partners, while infrastructure gaps in parts of the region can drive investment in contingency planning and purpose-built storage nodes.

Asia-Pacific delivers a heterogeneous mix of advanced hubs and emerging markets. Rapid vaccine rollouts and biotechnology innovation have accelerated investments in ultra-low and cryogenic storage in major markets, whereas emerging economies often require creative last-mile and packaging adaptations to contend with climatic variation and limited cold-room capacity. Across all regions, cross-border trade dynamics and trade policy changes influence network design, so a regionalized approach that blends centralized centers of excellence with local operational capacity reduces risk and improves responsiveness to demand shocks.

Competitive and collaborative company behaviors shaping the cold-chain pharmaceutical ecosystem including partnerships, specialization, and service differentiation

Company behaviors in the cold-chain pharmaceutical space reveal a mix of specialization, partnership and vertical integration as firms pursue competitive advantage. Some providers focus on deep technical niches-such as cryogenic logistics, ultra-low temperature storage or clinical-trial-centric services-investing in proprietary handling protocols, specialized equipment fleets and rigorous qualification programs to differentiate on product safety and reliability. Other players emphasize breadth, offering end-to-end solutions that combine storage, transport, compliance services and digital visibility, thereby simplifying supplier management for manufacturers and healthcare providers.

Strategic partnerships and alliances are increasingly common, enabling companies to marry local last-mile expertise with global air cargo and warehousing capabilities. Collaboration with technology vendors provides telemetry, predictive maintenance and analytic tooling that translate operational data into fewer temperature excursions and faster root-cause analysis. Meanwhile, a number of organizations pursue selective vertical integration-bringing storage or packaging capabilities in-house-to safeguard control over critical flows during product launches or pandemic-scale campaigns.

From the buyer perspective, selection criteria are shifting beyond price to emphasize demonstrable GDP compliance, lane validation experience, failure-mode analysis, and the ability to scale rapidly during demand surges. Companies that invest in cross-functional teams combining regulatory, quality and operations expertise are better positioned to win long-term engagements with manufacturers and health systems.

Actionable recommendations for senior executives to future-proof cold-chain operations through investment, partnerships, compliance, and workforce strategy

Leaders must adopt a multi-dimensional strategy to future-proof cold-chain operations and capture value in an increasingly demanding environment. First, prioritize investments in visibility and analytics that provide real-time telemetry across transport and storage, enabling proactive exception management and stronger audit trails. Complement technology investments with process controls, robust qualification protocols and recurring audits to ensure data is supported by validated procedures.

Second, pursue a regionalized network design that balances centralized centers of excellence for high-complexity products with localized last-mile capabilities to guarantee service continuity. Where trade policy or tariffs create volatility, nearshoring and diversified supplier strategies reduce exposure and shorten lead times. Third, update packaging and equipment policies to reflect evolving product mixes; specify active or passive packaging solutions aligned to temperature ranges from cryogenic to refrigerated 2-8 °C, and standardize equipment qualification across warehouses and transport assets to reduce variability.

Fourth, strengthen commercial contracts and procurement practices to include flexible terms for surge capacity, clear responsibilities for exception handling and shared obligations for qualification. Fifth, invest in workforce capability through targeted GDP training and cross-functional simulations that include quality, operations and regulatory teams, ensuring readiness for complex launches and emergency responses. Finally, embed sustainability objectives into CAPEX and lifecycle decisions, selecting energy-efficient equipment and circular packaging models where they also reinforce reliability and compliance.

Transparent research methodology detailing data sources, validation steps, stakeholder interviews, and analytical frameworks applied to cold-chain assessment

The research methodology combined primary and secondary evidence streams to create a rigorous, transparent foundation for analysis. Primary inputs included structured interviews with supply chain, quality and regulatory leaders across manufacturers, logistics providers and clinical trial organizations, supported by operational site visits and process walkthroughs that validated equipment, packaging and temperature-control practices. These interviews emphasized lane validation experiences, last-mile exceptions, and equipment qualification practices to capture real-world constraints and mitigation approaches.

Secondary sources comprised regulatory guidelines, technical standards, trade policy documents and equipment specifications that were synthesized to ensure alignment with current compliance expectations. A multi-step validation process reconciled interview findings with documentary evidence, and key assertions were cross-checked against multiple independent sources where available. Analytical frameworks incorporated failure-mode effects analysis for high-risk lanes, scenario-based planning for tariff and trade disruptions, and capability-matrix mapping to link product types to packaging and equipment requirements.

Throughout the process, care was taken to anonymize sensitive operational details and to prioritize reproducibility: assumptions and inclusion criteria are documented, and methodological limitations are acknowledged, including variability across jurisdictions and the rapid evolution of technology and regulatory practice.

Concluding synthesis of strategic implications, lingering risks, and pragmatic pathways for resilient and compliant cold-chain pharma delivery

In closing, the cold-chain pharmaceutical landscape is at an inflection point where product innovation, regulatory rigor and geopolitical dynamics collectively raise the bar for operational excellence. Organizations that proactively align investments in telemetry, validated packaging, and regional network flexibility will reduce risk and accelerate access to critical therapies. At the same time, trade policy volatility and increasing complexity in product portfolios require dynamic procurement, robust qualification practices and stronger contractual protections to maintain continuity.

Lingering risks include infrastructure variability across regions, talent shortages for specialized handling, and the potential for tariff or trade disruptions to disrupt established lanes. However, pragmatic pathways exist: prioritize auditable processes, cultivate partnerships that combine global reach with local execution, and invest in workforce and technology capabilities that translate data into decisive action. Executives who integrate these dimensions into a coherent strategic roadmap will not only protect product integrity but also create operational agility that supports rapid launches and resilient commercial supply.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Integration of blockchain-enabled tracking platforms for end-to-end cold-chain visibility and compliance
  • 5.2. Adoption of IoT-enabled smart packaging solutions to monitor critical temperature deviations in real time
  • 5.3. Scaling infrastructure for ultra-low temperature storage to support mRNA vaccine distribution at global scale
  • 5.4. Implementation of eco-friendly biodegradable thermal insulation materials in cold-chain transport packaging
  • 5.5. Strategic partnerships between biopharma companies and specialized 3PLs for last-mile temperature-controlled deliveries
  • 5.6. Regulatory harmonization efforts to streamline cross-border cold-chain pharma logistics and reduce compliance delays
  • 5.7. Acceleration of cryogenic chain-of-identity and custody for autologous cell and gene therapies from apheresis to infusion
  • 5.8. Deployment of AI-driven lane risk scoring and predictive ETD/ETA planning to preempt delays and excursion-prone routings
  • 5.9. Airport and airline investments in CEIV Pharma facilities and cool dollies to protect ramp integrity for pharma consignments
  • 5.10. Use of digital twins and stability modeling to design robust cold-chain flows and proactively manage cumulative thermal exposure

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Cold-chain Pharma Market, by Product Type

  • 8.1. Introduction
  • 8.2. Biologics
    • 8.2.1. Monoclonal Antibodies
    • 8.2.2. Plasma-Derived Therapeutics
    • 8.2.3. Recombinant Proteins & Enzymes
  • 8.3. Blood & Plasma Products
    • 8.3.1. Coagulation Factors
    • 8.3.2. Immunoglobulins
  • 8.4. Cell & Gene Therapies
    • 8.4.1. Allogeneic Cell Therapies
    • 8.4.2. Autologous Cell Therapies
    • 8.4.3. Gene Therapies
  • 8.5. Clinical Trial Materials
    • 8.5.1. Ancillaries & Kits
    • 8.5.2. Investigational Medicinal Products
  • 8.6. Insulins & Hormones
    • 8.6.1. GLP-1 & Other Peptide Hormones
    • 8.6.2. Insulin
  • 8.7. Specialty Pharmaceuticals
    • 8.7.1. Fertility & Reproductive Medicines
    • 8.7.2. Specialty Injectables
  • 8.8. Vaccines
    • 8.8.1. Pandemic & Emerging Vaccines
      • 8.8.1.1. mRNA Vaccines
      • 8.8.1.2. Viral Vector Vaccines
    • 8.8.2. Routine Immunization Vaccines
    • 8.8.3. Travel & Specialty Vaccines

9. Cold-chain Pharma Market, by Packaging Type

  • 9.1. Introduction
  • 9.2. Active Packaging
  • 9.3. Passive Packaging

10. Cold-chain Pharma Market, by Temperature Range

  • 10.1. Introduction
  • 10.2. Cryogenic (<= -150 °C)
    • 10.2.1. Cryo Packaging
    • 10.2.2. Dry Shipper Transport
    • 10.2.3. LN2 Vapor Storage
  • 10.3. Frozen (-20 To -40 °C)
    • 10.3.1. Packaging
    • 10.3.2. Storage
    • 10.3.3. Transportation
  • 10.4. Refrigerated (2-8 °C)
    • 10.4.1. Packaging
    • 10.4.2. Storage
    • 10.4.3. Transportation
  • 10.5. Ultra-Low (-60 To -86 °C)
    • 10.5.1. Packaging
    • 10.5.2. Storage
    • 10.5.3. Transportation

11. Cold-chain Pharma Market, by Equipment

  • 11.1. Introduction
  • 11.2. Storage Equipment
    • 11.2.1. Cold Rooms & Warehouses
    • 11.2.2. Cryogenic Freezers & LN2 Tanks
    • 11.2.3. Freezers (-20 °C Class)
    • 11.2.4. Pharmaceutical Refrigerators (2-8 °C)
    • 11.2.5. ULT Freezers (-80 °C Class)
  • 11.3. Transport Equipment
    • 11.3.1. Air Cargo Containers (ULDs)
    • 11.3.2. Last-Mile Portable Coolers
    • 11.3.3. Ocean Reefer Containers
    • 11.3.4. Reefer Trucks & Vans

12. Cold-chain Pharma Market, by Service Type

  • 12.1. Introduction
  • 12.2. Clinical Trial Logistics
    • 12.2.1. Ancillary Management
    • 12.2.2. Direct-To-Patient Services
    • 12.2.3. Site Supply And Returns
  • 12.3. Compliance & Quality
    • 12.3.1. Audits & GDP Training
    • 12.3.2. Lane Validation & Risk Assessment
    • 12.3.3. Qualification (IQ/OQ/PQ)
  • 12.4. Storage & Warehousing
    • 12.4.1. Cryogenic Storage
    • 12.4.2. Long-Term GMP Storage
  • 12.5. Transportation
    • 12.5.1. First-Mile Pickup
    • 12.5.2. Last-Mile Delivery
    • 12.5.3. Line-Haul Transport
    • 12.5.4. Reverse Logistics & Returns

13. Cold-chain Pharma Market, by Application

  • 13.1. Introduction
  • 13.2. Clinical Trials
  • 13.3. Commercial Distribution
  • 13.4. Direct-To-Patient/Home Delivery
  • 13.5. Humanitarian & NGO Supply
  • 13.6. Specialty Pharmacy Fulfillment
  • 13.7. Vaccination Campaigns

14. Cold-chain Pharma Market, by End User

  • 14.1. Introduction
  • 14.2. Blood Banks & Plasma Centers
  • 14.3. Clinical Trial Sites & Depots
  • 14.4. CMOs & CDMOs
  • 14.5. CROs
  • 14.6. Hospitals & Clinics
  • 14.7. Pharma & Biotech Manufacturers
    • 14.7.1. Emerging Biotech
    • 14.7.2. Large Pharmaceutical Companies
  • 14.8. Retail & Specialty Pharmacies
  • 14.9. Vaccination Centers & Public Health Agencies

15. Americas Cold-chain Pharma Market

  • 15.1. Introduction
  • 15.2. United States
  • 15.3. Canada
  • 15.4. Mexico
  • 15.5. Brazil
  • 15.6. Argentina

16. Europe, Middle East & Africa Cold-chain Pharma Market

  • 16.1. Introduction
  • 16.2. United Kingdom
  • 16.3. Germany
  • 16.4. France
  • 16.5. Russia
  • 16.6. Italy
  • 16.7. Spain
  • 16.8. United Arab Emirates
  • 16.9. Saudi Arabia
  • 16.10. South Africa
  • 16.11. Denmark
  • 16.12. Netherlands
  • 16.13. Qatar
  • 16.14. Finland
  • 16.15. Sweden
  • 16.16. Nigeria
  • 16.17. Egypt
  • 16.18. Turkey
  • 16.19. Israel
  • 16.20. Norway
  • 16.21. Poland
  • 16.22. Switzerland

17. Asia-Pacific Cold-chain Pharma Market

  • 17.1. Introduction
  • 17.2. China
  • 17.3. India
  • 17.4. Japan
  • 17.5. Australia
  • 17.6. South Korea
  • 17.7. Indonesia
  • 17.8. Thailand
  • 17.9. Philippines
  • 17.10. Malaysia
  • 17.11. Singapore
  • 17.12. Vietnam
  • 17.13. Taiwan

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. DHL International GmbH
    • 18.3.2. FedEx Corporation
    • 18.3.3. Americold Realty Trust, Inc.
    • 18.3.4. AmerisourceBergen Corporation
    • 18.3.5. C.H. Robinson Worldwide, Inc.
    • 18.3.6. Catalent, Inc.
    • 18.3.7. Clinigen Group PLC
    • 18.3.8. Conestoga Cold Storage Ltd.
    • 18.3.9. Continental AG
    • 18.3.10. CWT Ltd.
    • 18.3.11. DB Schenker
    • 18.3.12. DSV A/S
    • 18.3.13. Emergent Cold LatAm Management LLC
    • 18.3.14. HCL Technologies Limited
    • 18.3.15. Helapet ltd.
    • 18.3.16. Interstate Cold Storage, Inc.
    • 18.3.17. JWD InfoLogistics Public Co. Ltd.
    • 18.3.18. Keppel Telecommunications & Transportation Ltd,
    • 18.3.19. Kerry Logistics Network Limited by SF Holding Co., Ltd.
    • 18.3.20. Kuehne + Nagel Management AG
    • 18.3.21. Lineage, Inc.
    • 18.3.22. Maersk A/S
    • 18.3.23. NewCold Cooperatief UA
    • 18.3.24. OOCL Logistics Limited by COSCO SHIPPING Holdings Co. Limited
    • 18.3.25. SCG Logistics Management Co Ltd.
    • 18.3.26. Tiong Nam Logistics Holdings Berhad
    • 18.3.27. United Parcel Service, Inc.
    • 18.3.28. Ych Group
    • 18.3.29. Yusen Logistics Group
    • 18.3.30. BioCold Technologies S.A.S
    • 18.3.31. FreezPak Logistics

19. ResearchAI

20. ResearchStatistics

21. ResearchContacts

22. ResearchArticles

23. Appendix

LIST OF FIGURES

  • FIGURE 1. COLD-CHAIN PHARMA MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING TYPE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TEMPERATURE RANGE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TEMPERATURE RANGE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY EQUIPMENT, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY EQUIPMENT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 18. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 22. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA COLD-CHAIN PHARMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA COLD-CHAIN PHARMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 26. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 27. COLD-CHAIN PHARMA MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. COLD-CHAIN PHARMA MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 29. COLD-CHAIN PHARMA MARKET: RESEARCHAI
  • FIGURE 30. COLD-CHAIN PHARMA MARKET: RESEARCHSTATISTICS
  • FIGURE 31. COLD-CHAIN PHARMA MARKET: RESEARCHCONTACTS
  • FIGURE 32. COLD-CHAIN PHARMA MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. COLD-CHAIN PHARMA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PLASMA-DERIVED THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PLASMA-DERIVED THERAPEUTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY RECOMBINANT PROTEINS & ENZYMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY RECOMBINANT PROTEINS & ENZYMES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD & PLASMA PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD & PLASMA PRODUCTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COAGULATION FACTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COAGULATION FACTORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD & PLASMA PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD & PLASMA PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CELL & GENE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CELL & GENE THERAPIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ALLOGENEIC CELL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ALLOGENEIC CELL THERAPIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY AUTOLOGOUS CELL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY AUTOLOGOUS CELL THERAPIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY GENE THERAPIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CELL & GENE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CELL & GENE THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL MATERIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL MATERIALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ANCILLARIES & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ANCILLARIES & KITS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY INVESTIGATIONAL MEDICINAL PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY INVESTIGATIONAL MEDICINAL PRODUCTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL MATERIALS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL MATERIALS, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY INSULINS & HORMONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY INSULINS & HORMONES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY GLP-1 & OTHER PEPTIDE HORMONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY GLP-1 & OTHER PEPTIDE HORMONES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY INSULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY INSULIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY INSULINS & HORMONES, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY INSULINS & HORMONES, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACEUTICALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FERTILITY & REPRODUCTIVE MEDICINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FERTILITY & REPRODUCTIVE MEDICINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY INJECTABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY INJECTABLES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACEUTICALS, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PANDEMIC & EMERGING VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PANDEMIC & EMERGING VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY MRNA VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PANDEMIC & EMERGING VACCINES, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PANDEMIC & EMERGING VACCINES, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ROUTINE IMMUNIZATION VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ROUTINE IMMUNIZATION VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRAVEL & SPECIALTY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRAVEL & SPECIALTY VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ACTIVE PACKAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ACTIVE PACKAGING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PASSIVE PACKAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PASSIVE PACKAGING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TEMPERATURE RANGE, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TEMPERATURE RANGE, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC (<= -150 °C), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC (<= -150 °C), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYO PACKAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYO PACKAGING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY DRY SHIPPER TRANSPORT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY DRY SHIPPER TRANSPORT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LN2 VAPOR STORAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LN2 VAPOR STORAGE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC (<= -150 °C), 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC (<= -150 °C), 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FROZEN (-20 TO -40 °C), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FROZEN (-20 TO -40 °C), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FROZEN (-20 TO -40 °C), 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FROZEN (-20 TO -40 °C), 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REFRIGERATED (2-8 °C), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REFRIGERATED (2-8 °C), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 115. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REFRIGERATED (2-8 °C), 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REFRIGERATED (2-8 °C), 2025-2030 (USD MILLION)
  • TABLE 117. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ULTRA-LOW (-60 TO -86 °C), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ULTRA-LOW (-60 TO -86 °C), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 119. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 121. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 123. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 125. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ULTRA-LOW (-60 TO -86 °C), 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ULTRA-LOW (-60 TO -86 °C), 2025-2030 (USD MILLION)
  • TABLE 127. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY EQUIPMENT, 2025-2030 (USD MILLION)
  • TABLE 129. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE EQUIPMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 131. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COLD ROOMS & WAREHOUSES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COLD ROOMS & WAREHOUSES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 133. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC FREEZERS & LN2 TANKS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC FREEZERS & LN2 TANKS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 135. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FREEZERS (-20 °C CLASS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FREEZERS (-20 °C CLASS), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 137. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PHARMACEUTICAL REFRIGERATORS (2-8 °C), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PHARMACEUTICAL REFRIGERATORS (2-8 °C), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 139. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ULT FREEZERS (-80 °C CLASS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ULT FREEZERS (-80 °C CLASS), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 141. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE EQUIPMENT, 2025-2030 (USD MILLION)
  • TABLE 143. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORT EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORT EQUIPMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 145. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY AIR CARGO CONTAINERS (ULDS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY AIR CARGO CONTAINERS (ULDS), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 147. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LAST-MILE PORTABLE COOLERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LAST-MILE PORTABLE COOLERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 149. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY OCEAN REEFER CONTAINERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY OCEAN REEFER CONTAINERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 151. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REEFER TRUCKS & VANS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REEFER TRUCKS & VANS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 153. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORT EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORT EQUIPMENT, 2025-2030 (USD MILLION)
  • TABLE 155. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 157. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL LOGISTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL LOGISTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 159. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ANCILLARY MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ANCILLARY MANAGEMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 161. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY DIRECT-TO-PATIENT SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY DIRECT-TO-PATIENT SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 163. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SITE SUPPLY AND RETURNS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SITE SUPPLY AND RETURNS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 165. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL LOGISTICS, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL LOGISTICS, 2025-2030 (USD MILLION)
  • TABLE 167. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COMPLIANCE & QUALITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COMPLIANCE & QUALITY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 169. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY AUDITS & GDP TRAINING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY AUDITS & GDP TRAINING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 171. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LANE VALIDATION & RISK ASSESSMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LANE VALIDATION & RISK ASSESSMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 173. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY QUALIFICATION (IQ/OQ/PQ), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY QUALIFICATION (IQ/OQ/PQ), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 175. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COMPLIANCE & QUALITY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COMPLIANCE & QUALITY, 2025-2030 (USD MILLION)
  • TABLE 177. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE & WAREHOUSING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE & WAREHOUSING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 179. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC STORAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC STORAGE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 181. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LONG-TERM GMP STORAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LONG-TERM GMP STORAGE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 183. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE & WAREHOUSING, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE & WAREHOUSING, 2025-2030 (USD MILLION)
  • TABLE 185. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 187. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FIRST-MILE PICKUP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FIRST-MILE PICKUP, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 189. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LAST-MILE DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LAST-MILE DELIVERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 191. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LINE-HAUL TRANSPORT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LINE-HAUL TRANSPORT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 193. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REVERSE LOGISTICS & RETURNS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REVERSE LOGISTICS & RETURNS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 195. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, 2025-2030 (USD MILLION)
  • TABLE 197. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 199. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 201. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COMMERCIAL DISTRIBUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COMMERCIAL DISTRIBUTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 203. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY DIRECT-TO-PATIENT/HOME DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY DIRECT-TO-PATIENT/HOME DELIVERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 205. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY HUMANITARIAN & NGO SUPPLY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY HUMANITARIAN & NGO SUPPLY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 207. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACY FULFILLMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACY FULFILLMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 209. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VACCINATION CAMPAIGNS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VACCINATION CAMPAIGNS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 211. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 213. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD BANKS & PLASMA CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD BANKS & PLASMA CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 215. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL SITES & DEPOTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL SITES & DEPOTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 217. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CMOS & CDMOS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CMOS & CDMOS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 219. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CROS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CROS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 221. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 223. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PHARMA & BIOTECH MANUFACTURERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PHARMA & BIOTECH MANUFACTURERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 225. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY EMERGING BIOTECH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY EMERGING BIOTECH, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 227. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LARGE PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LARGE PHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 229. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PHARMA & BIOTECH MANUFACTURERS, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PHARMA & BIOTECH MANUFACTURERS, 2025-2030 (USD MILLION)
  • TABLE 231. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY RETAIL & SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY RETAIL & SPECIALTY PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 233. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VACCINATION CENTERS & PUBLIC HEALTH AGENCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VACCINATION CENTERS & PUBLIC HEALTH AGENCIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 235. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 237. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 239. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD & PLASMA PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD & PLASMA PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 241. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY CELL & GENE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY CELL & GENE THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 243. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL MATERIALS, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL MATERIALS, 2025-2030 (USD MILLION)
  • TABLE 245. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY INSULINS & HORMONES, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY INSULINS & HORMONES, 2025-2030 (USD MILLION)
  • TABLE 247. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACEUTICALS, 2025-2030 (USD MILLION)
  • TABLE 249. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 251. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY PANDEMIC & EMERGING VACCINES, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY PANDEMIC & EMERGING VACCINES, 2025-2030 (USD MILLION)
  • TABLE 253. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
  • TABLE 255. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY TEMPERATURE RANGE, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY TEMPERATURE RANGE, 2025-2030 (USD MILLION)
  • TABLE 257. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC (<= -150 °C), 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC (<= -150 °C), 2025-2030 (USD MILLION)
  • TABLE 259. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY FROZEN (-20 TO -40 °C), 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY FROZEN (-20 TO -40 °C), 2025-2030 (USD MILLION)
  • TABLE 261. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY REFRIGERATED (2-8 °C), 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY REFRIGERATED (2-8 °C), 2025-2030 (USD MILLION)
  • TABLE 263. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY ULTRA-LOW (-60 TO -86 °C), 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY ULTRA-LOW (-60 TO -86 °C), 2025-2030 (USD MILLION)
  • TABLE 265. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY EQUIPMENT, 2025-2030 (USD MILLION)
  • TABLE 267. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE EQUIPMENT, 2025-2030 (USD MILLION)
  • TABLE 269. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORT EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORT EQUIPMENT, 2025-2030 (USD MILLION)
  • TABLE 271. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 273. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL LOGISTICS, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL LOGISTICS, 2025-2030 (USD MILLION)
  • TABLE 275. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY COMPLIANCE & QUALITY, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY COMPLIANCE & QUALITY, 2025-2030 (USD MILLION)
  • TABLE 277. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE & WAREHOUSING, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE & WAREHOUSING, 2025-2030 (USD MILLION)
  • TABLE 279. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, 2025-2030 (USD MILLION)
  • TABLE 281. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 283. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 285. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY PHARMA & BIOTECH MANUFACTURERS, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY PHARMA & BIOTECH MANUFACTURERS, 2025-2030 (USD MILLION)
  • TABLE 287. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 289. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 291. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 292. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 293. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD & PLASMA PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD & PLASMA PRODUCTS, 2025-2030 (USD MILLION)
  • TABLE 295. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY CELL & GENE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 296. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY CELL & GENE THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 297. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL MATERIALS, 2018-2024 (USD MILLION)
  • TABLE 298. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL MATERIALS, 2025-2030 (USD MILLION)
  • TABLE 299. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY INSULINS & HORMONES, 2018-2024 (USD MILLION)
  • TABLE 300. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY INSULINS & HORMONES, 2025-2030 (USD MILLION)
  • TABLE 301. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 302. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACEUTICALS, 2025-2030 (USD MILLION)
  • TABLE 303. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 304. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 305. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY PANDEMIC & EMERGING VACCINES, 2018-2024 (USD MILLION)
  • TABLE 306. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY PANDEMIC & EMERGING VACCINES, 2025-2030 (USD MILLION)
  • TABLE 307. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING TYPE, 2025-2030 (USD MILLION)
  • TABLE 309. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY TEMPERATURE RANGE, 2018-2024 (USD MILLION)
  • TABLE 310. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY TEMPERATURE RANGE, 2025-2030 (USD MILLION)
  • TABLE 311. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC (<= -150 °C), 2018-2024 (USD MILLION)
  • TABLE 312. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC (<= -150 °C), 2025-2030 (USD MILLION)
  • TABLE 313. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY FROZEN (-20 TO -40 °C), 2018-2024 (USD MILLION)
  • TABLE 314. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY FROZEN (-20 TO -40 °C), 2025-2030 (USD MILLION)
  • TABLE 315. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, BY REFRIGERATED (2-8 °C), 2018-2024 (USD MILLION)
  • TABLE 316. UNITED STATES COLD-